NOSH‐aspirin (NBS‐1120), a novel nitric oxide and hydrogen sulfide releasing hybrid, attenuates neuroinflammation induced by microglial and astrocytic activation: A new candidate for treatment of neurodegenerative disorders
Identifieur interne : 000F69 ( Main/Curation ); précédent : 000F68; suivant : 000F70NOSH‐aspirin (NBS‐1120), a novel nitric oxide and hydrogen sulfide releasing hybrid, attenuates neuroinflammation induced by microglial and astrocytic activation: A new candidate for treatment of neurodegenerative disorders
Auteurs : Moonhee Lee [Canada] ; Edith Mcgeer [Canada] ; Ravinder Kodela [États-Unis] ; Khosrow Kashfi [États-Unis] ; Patrick L. Mcgeer [Canada]Source :
- Glia [ 0894-1491 ] ; 2013-10.
English descriptors
- KwdEn :
- Anti-Inflammatory Agents (pharmacology), Aspirin (analogs & derivatives), Aspirin (pharmacology), Astrocytes (drug effects), Astrocytoma (pathology), Cell Line, Tumor, Cells, Cultured, Disulfides (pharmacology), Dose-Response Relationship, Drug, Humans, Interferon-gamma (pharmacology), Interleukin-6 (metabolism), Lipopolysaccharides (pharmacology), Microglia (drug effects), NF-kappa B (metabolism), Nitrates (pharmacology), Signal Transduction (drug effects), Temporal Lobe (cytology), Time Factors, Tumor Necrosis Factor-alpha (metabolism), p38 Mitogen-Activated Protein Kinases (metabolism).
- MESH :
- chemical , analogs & derivatives : Aspirin.
- chemical , metabolism : Interleukin-6, NF-kappa B, Tumor Necrosis Factor-alpha, p38 Mitogen-Activated Protein Kinases.
- chemical , pharmacology : Anti-Inflammatory Agents, Aspirin, Disulfides, Interferon-gamma, Lipopolysaccharides, Nitrates.
- cytology : Temporal Lobe.
- drug effects : Astrocytes, Microglia, Signal Transduction.
- pathology : Astrocytoma.
- Cell Line, Tumor, Cells, Cultured, Dose-Response Relationship, Drug, Humans, Time Factors.
Abstract
Hydrogen sulfide (H2S) and nitric oxide (NO) have been described as gasotransmitters. Anti‐inflammatory activity in the central and peripheral nervous systems may be one of their functions. Previously we demonstrated that several SH‐ donors including H2S‐releasing aspirin (S‐ASA) exhibited anti‐inflammatory and neuroprotective activity in vitro against toxins released by activated microglia and astrocytes. Here we report that NOSH‐ASA, an NO‐ and H2S‐releasing hybrid of aspirin, has a significantly greater anti‐inflammatory and neuroprotective effect than S‐ASA or NO‐ASA. When activated by LPS/IFNγ, human microglia and THP‐1 cells release materials that are toxic to differentiated SH‐SY5Y cells. These phenomena also occur with IFNγ‐stimulated human astroglia and U373 cells. When the cells were treated with the S‐ASA or NO‐ASA, there was a significant enhancement of neuroprotection. However, NOSH‐ASA had significantly more potent protection properties than NO‐ASA or S‐ASA. The effect was concentration‐dependent, as well as incubation time‐dependent. Such treatment not only reduced the release of the TNFα and IL‐6, but also attenuated activation of P38 MAPK and NFκB proteins. All the compounds tested were not harmful when applied directly to SH‐SY5Y cells. These data suggest that NOSH‐ASA has significant anti‐inflammatory properties and may be a new candidate for treating neurodegenerative disorders that have a prominent neuroinflammatory component such as Alzheimer disease and Parkinson disease. GLIA 2013;61:1724–1734
Url:
DOI: 10.1002/glia.22553
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000893
- to stream Istex, to step Curation: Pour aller vers cette notice dans l'étape Curation :000893
- to stream Istex, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000087
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000856
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :000856
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000856
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :001529
- to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :001529
- to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001529
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :000F81
Links to Exploration step
ISTEX:B9BD99BC43ADC00231A3187A23F5405E9824283ALe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">NOSH‐aspirin (NBS‐1120), a novel nitric oxide and hydrogen sulfide releasing hybrid, attenuates neuroinflammation induced by microglial and astrocytic activation: A new candidate for treatment of neurodegenerative disorders</title>
<author><name sortKey="Lee, Moonhee" sort="Lee, Moonhee" uniqKey="Lee M" first="Moonhee" last="Lee">Moonhee Lee</name>
</author>
<author><name sortKey="Mcgeer, Edith" sort="Mcgeer, Edith" uniqKey="Mcgeer E" first="Edith" last="Mcgeer">Edith Mcgeer</name>
</author>
<author><name sortKey="Kodela, Ravinder" sort="Kodela, Ravinder" uniqKey="Kodela R" first="Ravinder" last="Kodela">Ravinder Kodela</name>
</author>
<author><name sortKey="Kashfi, Khosrow" sort="Kashfi, Khosrow" uniqKey="Kashfi K" first="Khosrow" last="Kashfi">Khosrow Kashfi</name>
</author>
<author><name sortKey="Mcgeer, Patrick L" sort="Mcgeer, Patrick L" uniqKey="Mcgeer P" first="Patrick L." last="Mcgeer">Patrick L. Mcgeer</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:B9BD99BC43ADC00231A3187A23F5405E9824283A</idno>
<date when="2013" year="2013">2013</date>
<idno type="doi">10.1002/glia.22553</idno>
<idno type="url">https://api-v5.istex.fr/document/B9BD99BC43ADC00231A3187A23F5405E9824283A/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000893</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000893</idno>
<idno type="wicri:Area/Istex/Curation">000893</idno>
<idno type="wicri:Area/Istex/Checkpoint">000087</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000087</idno>
<idno type="wicri:doubleKey">0894-1491:2013:Lee M:nosh:aspirin:nbs</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:23918470</idno>
<idno type="wicri:Area/PubMed/Corpus">000856</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000856</idno>
<idno type="wicri:Area/PubMed/Curation">000856</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000856</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000856</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000856</idno>
<idno type="wicri:Area/Ncbi/Merge">001529</idno>
<idno type="wicri:Area/Ncbi/Curation">001529</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001529</idno>
<idno type="wicri:Area/Main/Merge">000F81</idno>
<idno type="wicri:Area/Main/Curation">000F69</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">NOSH‐aspirin (NBS‐1120), a novel nitric oxide and hydrogen sulfide releasing hybrid, attenuates neuroinflammation induced by microglial and astrocytic activation: A new candidate for treatment of neurodegenerative disorders</title>
<author><name sortKey="Lee, Moonhee" sort="Lee, Moonhee" uniqKey="Lee M" first="Moonhee" last="Lee">Moonhee Lee</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Kinsmen Laboratory of Neurological Research, University of British Columbia, BC, V6T 1Z3, Vancouver</wicri:regionArea>
<wicri:noRegion>Vancouver</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mcgeer, Edith" sort="Mcgeer, Edith" uniqKey="Mcgeer E" first="Edith" last="Mcgeer">Edith Mcgeer</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Kinsmen Laboratory of Neurological Research, University of British Columbia, BC, V6T 1Z3, Vancouver</wicri:regionArea>
<wicri:noRegion>Vancouver</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kodela, Ravinder" sort="Kodela, Ravinder" uniqKey="Kodela R" first="Ravinder" last="Kodela">Ravinder Kodela</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Department of Physiology, Pharmacology and Neuroscience, Sophie Davis School of Biomedical Education, City University of New York Medical School, 10031, New York</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Kashfi, Khosrow" sort="Kashfi, Khosrow" uniqKey="Kashfi K" first="Khosrow" last="Kashfi">Khosrow Kashfi</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Department of Physiology, Pharmacology and Neuroscience, Sophie Davis School of Biomedical Education, City University of New York Medical School, 10031, New York</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Mcgeer, Patrick L" sort="Mcgeer, Patrick L" uniqKey="Mcgeer P" first="Patrick L." last="Mcgeer">Patrick L. Mcgeer</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Kinsmen Laboratory of Neurological Research, University of British Columbia, BC, V6T 1Z3, Vancouver</wicri:regionArea>
<wicri:noRegion>Vancouver</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country wicri:rule="url">Canada</country>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Glia</title>
<title level="j" type="abbrev">Glia</title>
<idno type="ISSN">0894-1491</idno>
<idno type="eISSN">1098-1136</idno>
<imprint><publisher>Blackwell Publishing Ltd</publisher>
<date type="published" when="2013-10">2013-10</date>
<biblScope unit="volume">61</biblScope>
<biblScope unit="issue">10</biblScope>
<biblScope unit="page" from="1724">1724</biblScope>
<biblScope unit="page" to="1734">1734</biblScope>
</imprint>
<idno type="ISSN">0894-1491</idno>
</series>
<idno type="istex">B9BD99BC43ADC00231A3187A23F5405E9824283A</idno>
<idno type="DOI">10.1002/glia.22553</idno>
<idno type="ArticleID">GLIA22553</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0894-1491</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anti-Inflammatory Agents (pharmacology)</term>
<term>Aspirin (analogs & derivatives)</term>
<term>Aspirin (pharmacology)</term>
<term>Astrocytes (drug effects)</term>
<term>Astrocytoma (pathology)</term>
<term>Cell Line, Tumor</term>
<term>Cells, Cultured</term>
<term>Disulfides (pharmacology)</term>
<term>Dose-Response Relationship, Drug</term>
<term>Humans</term>
<term>Interferon-gamma (pharmacology)</term>
<term>Interleukin-6 (metabolism)</term>
<term>Lipopolysaccharides (pharmacology)</term>
<term>Microglia (drug effects)</term>
<term>NF-kappa B (metabolism)</term>
<term>Nitrates (pharmacology)</term>
<term>Signal Transduction (drug effects)</term>
<term>Temporal Lobe (cytology)</term>
<term>Time Factors</term>
<term>Tumor Necrosis Factor-alpha (metabolism)</term>
<term>p38 Mitogen-Activated Protein Kinases (metabolism)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Aspirin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Interleukin-6</term>
<term>NF-kappa B</term>
<term>Tumor Necrosis Factor-alpha</term>
<term>p38 Mitogen-Activated Protein Kinases</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Anti-Inflammatory Agents</term>
<term>Aspirin</term>
<term>Disulfides</term>
<term>Interferon-gamma</term>
<term>Lipopolysaccharides</term>
<term>Nitrates</term>
</keywords>
<keywords scheme="MESH" qualifier="cytology" xml:lang="en"><term>Temporal Lobe</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Astrocytes</term>
<term>Microglia</term>
<term>Signal Transduction</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Astrocytoma</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Cell Line, Tumor</term>
<term>Cells, Cultured</term>
<term>Dose-Response Relationship, Drug</term>
<term>Humans</term>
<term>Time Factors</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract">Hydrogen sulfide (H2S) and nitric oxide (NO) have been described as gasotransmitters. Anti‐inflammatory activity in the central and peripheral nervous systems may be one of their functions. Previously we demonstrated that several SH‐ donors including H2S‐releasing aspirin (S‐ASA) exhibited anti‐inflammatory and neuroprotective activity in vitro against toxins released by activated microglia and astrocytes. Here we report that NOSH‐ASA, an NO‐ and H2S‐releasing hybrid of aspirin, has a significantly greater anti‐inflammatory and neuroprotective effect than S‐ASA or NO‐ASA. When activated by LPS/IFNγ, human microglia and THP‐1 cells release materials that are toxic to differentiated SH‐SY5Y cells. These phenomena also occur with IFNγ‐stimulated human astroglia and U373 cells. When the cells were treated with the S‐ASA or NO‐ASA, there was a significant enhancement of neuroprotection. However, NOSH‐ASA had significantly more potent protection properties than NO‐ASA or S‐ASA. The effect was concentration‐dependent, as well as incubation time‐dependent. Such treatment not only reduced the release of the TNFα and IL‐6, but also attenuated activation of P38 MAPK and NFκB proteins. All the compounds tested were not harmful when applied directly to SH‐SY5Y cells. These data suggest that NOSH‐ASA has significant anti‐inflammatory properties and may be a new candidate for treating neurodegenerative disorders that have a prominent neuroinflammatory component such as Alzheimer disease and Parkinson disease. GLIA 2013;61:1724–1734</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F69 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 000F69 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Canada |area= ParkinsonCanadaV1 |flux= Main |étape= Curation |type= RBID |clé= ISTEX:B9BD99BC43ADC00231A3187A23F5405E9824283A |texte= NOSH‐aspirin (NBS‐1120), a novel nitric oxide and hydrogen sulfide releasing hybrid, attenuates neuroinflammation induced by microglial and astrocytic activation: A new candidate for treatment of neurodegenerative disorders }}
This area was generated with Dilib version V0.6.29. |